No Data
RemeGen's 2024 Loss Narrows as Revenue Surges 58%
Rongchang Biotech: Rongchang Biopharmaceutical (Yantai) Co., Ltd. 2024 Annual Results Express Announcement
Rongchang Biopharmaceutical (Yantai) Co., Ltd. 2024 Annual Results Express Announcement
REMEGEN: INSIDE INFORMATION-2024 ANNUAL RESULTS UPDATE ANNOUNCEMENT
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
RemeGen Co., Ltd.'s (HKG:9995) Shares Bounce 33% But Its Business Still Trails The Industry
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
